Showing 5241-5250 of 8923 results for "".
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Asana BioSciences’ JAK/SYK Inhibitor Performs Well in Phase 2b Study of Hand Eczemahttps://practicaldermatology.com/news/asana-biosciences-jaksyk-inhibitor-performs-well-in-phase-2b-study-of-hand-eczema/2460409/Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adult patients with moderate-to-severe chronic hand eczema. The study was a randomiz
- Zilxi Approved: First Topical Minocycline Treatment for Rosaceahttps://practicaldermatology.com/news/zilxi-approved-first-topical-minocycline-treatment-for-rosacea/2460408/The FDA has approved Zilxi™ (minocycline) topical foam, 1.5%, from Menlo Therapeutics for the treatment of inflammatory lesions of rosacea in adults. Zilxi, developed as FMX103 by Menlo’s wholly-owned subsidiary Foamix Pharmaceuticals Ltd., is the first minocycline product of any kind
- ASLMS Names New Boardhttps://practicaldermatology.com/news/aslms-names-new-board/2460406/The American Society for Laser Medicine and Surgery (ASLMS) announced its new board during the Board of Directors meeting on April 30, 2020. Thomas E. Rohrer, MD is the new President of ASLMS is the world's largest professional organization dedicated to promoting research, education, and high
- FDA Approves Dupixent for Children Aged 6 to 11 Years with Moderate-to-Severe ADhttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-aged-6-to-11-years-with-moderate-to-severe-ad/2460404/The US Food and Drug Administration (FDA) gave its nod to Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Dupixent comes in two doses, prescribed based on weight (300 mg every four weeks for children ≥15 to <30 kg and 200 mg eve
- Crayola Announces New "Colors of the World" Crayons To Help Advance "Skinclusion"https://practicaldermatology.com/news/crayola-announces-new-colors-of-the-world-crayons-to-help-advance-skinclusion/2460402/Crayola is launching Colors of the World crayons—24 new crayons designed to represent more than 40 global skin tones across the world. The crayon packs feature side panels that serve as color references. Each crayon is wrapped in a gradient skin tone label with the color
- Congrats: Dr. Paul Bergstresser Receives ASA’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-paul-bergstresser-receives-asas-david-martin-carter-mentor-award/2460401/Dr. Paul Bergstresser of UT Southwestern Medical Center in Dallas, Texas is the recipient of the American Skin Association’s (ASA) 2020 David Martin Carter Mentor Award Since 1989, ASA's David Martin Carter Mentor Award has honored members of the derma
- Breaking Business News: Revance to Acquire HintMDhttps://practicaldermatology.com/news/breaking-business-news-revance-to-aquire-hintmd/2460399/Revance Therapeutics, Inc. has acquired HintMD, a financial technology platform for the aesthetics industry. Revance has agreed to pay HintMD’s shareholders a total of 8.54 million shares of Revance common stock, subject to customary adjustments provided in the acquisition agreeme
- Industry Responds to COVID-19: Dial Donates Products to FEMA, Encourages Americans to Participate in #IWashMyHandsFor Social Campaignhttps://practicaldermatology.com/news/industry-responds-dial-donates-products-to-fema-encourages-americans-to-participate-in-iwashmyhandsfor-social-campaign/2460398/Dial will donate more than 600,000 units of liquid hand soap, bar soap and body wash products to FEMA, supporting their mission to help people during disasters. In March 2020 Henkel announced a comprehensive
- Hoth Therapeutics Obtains Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/hoth-therapeutics-obtains-full-licensing-rights-for-biolexa-platform-atopic-dermatitis-treatment/2460397/Hoth Therapeutics, Inc. has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previo